ArticleClinical kidney journal2026
Urine albumin-to-creatinine ratio as a predictor of kidney function decline in Alport syndrome.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic kidney disease significantly impacts health and lifespan, but its progression remains difficult to predict. Therefore, there is a need for biomarkers to identify patients at risk of a rapid decline in kidney function. Alport syndrome (AS) exemplifies this challenge, as some patients experience rapid progression, while others exhibit a more gradual decline in kidney function. We hypothesized that urinary proteins, such as albumin, immunoglobulin G (IgG), or alpha-1-microglobulin, could serve as predictors of kidney function decline. Methods: This observational, non-interventional, retrospective study investigated 127 patients with AS from two centres. Yearly estimated glomerular filtration rate (eGFR) loss was modelled in a linear regression model. Results: Over a 42 ± 26-month follow-up, 24% of the patients had rapid eGFR decline (defined as a loss of >6 ml/min/1.73 m Conclusion: In this study, the amount of albuminuria was independently associated with the yearly loss of kidney function in patients with AS. Combined measurement of albuminuria and urinary IgG may identify patients with the highest risk of rapid decline in kidney function. Following external validation in a larger, prospective cohort, this approach could be used to identify patients who could potentially benefit from closer monitoring and earlier intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.